Recent Company News

• 09:14 AM ET Jun 12, 2025
  

  StreetAccount Summary - US Pre-market trading update

• 08:19 AM ET Jun 12, 2025
  

  StreetAccount Summary - US Pre-market trading

• 08:19 AM ET Aug 12, 2025
  

  Follow-up: Autolus Therapeutics reports Q2 EPS ($0.18) vs FactSet ($0.23); provides anticipated milestones - 8-K ($2.47, 0.00)

• 07:02 AM ET Aug 12, 2025
  

  Autolus Therapeutics reports Q2 EPS ($0.18) vs FactSet ($0.23) [8 est, ($0.30)-(0.19)] ($2.47, 0.00)

• 07:03 AM ET Jul 21, 2025
  

  Autolus Therapeutics' CAR T therapy AUCATZYL (Obecabtagene Autoleucel) granted European Marketing Authorization for adult patients (age 26 and older) with relapsed or refractory b-cell precursor acute Lymphoblastic Leukemia (R/R b-all) ($2.41, 0.00)

• 09:29 AM ET Jun 20, 2025
  

  Gene therapy reviewer at FDA's CBER escorted out on Wednesday